Brian McNamara Named Division Head, Novartis OTC
(Thomson Reuters ONE) -
Novartis International AG /
Brian McNamara Named Division Head, Novartis OTC
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Brian McNamara, who has held several key positions in the Novartis OTC
business over the past 7 years, succeeds Naomi Kelman
Basel, February 29, 2012 - Novartis named Brian McNamara to the position of
Division Head of Novartis OTC (Over-the-Counter), effective immediately.
McNamara replaces Naomi Kelman, who has decided to leave the company. Naomi
joined Novartis in March 2011 from Johnson & Johnson where she held several
roles in the Consumer, Medical Devices, and Diagnostic Sectors.
"I want to thank Naomi for her contributions to the business, and welcome Brian
as the new head of our OTC division," said Joseph Jimenez, CEO of Novartis.
"Novartis OTC is an important part of our broad healthcare portfolio and I am
confident that Brian will provide strong leadership, focusing on growing our
priority brands, consistently meeting our quality standards, and improving
performance in key emerging markets."
Brian McNamara has more than 20 years of experience in consumer marketing. He
started his career at Proctor & Gamble, where he spent several years in
manufacturing management. He later moved into brand management where he led a
number of P&G's Fabric Care businesses. Since joining Novartis OTC in 2004, Mr.
McNamara worked on a number of strategic initiatives, including the acquisition
of several OTC brands. He also played a key role in acquiring the rights to the
Prevacid® Rx-to-OTC switch. Mr. McNamara has a deep understanding of the
European OTC market, having served as Region Head of Novartis OTC Europe from
2007-2010.
Mr. McNamara will take on responsibility for continuing to drive growth in
Novartis OTC, ensuring high quality standards, as well as implementing
innovative marketing initiatives. Novartis OTC is a world leader in the
research, development, and marketing of OTC products. Novartis OTC has a robust
portfolio of cough, cold, respiratory disease, digestive health and pain
management medication as well as skin care products, smoking-cessation
treatments and mineral supplements. Key OTC brands include Theraflu®,
Triaminic®, Maalox®, Ex-Lax®, Gas-X®, Prevacid 24HR®, Excedrin® and Voltaren ®.
Disclaimer
This presentation contains forward-looking statements that can be identified by
terminology such as "confident," "will," "continuing," "ensuring,"
"implementing," or similar expressions, or by express or implied discussions
regarding potential future sales or earnings of the Novartis Group or any of the
OTC Division; or by discussions of strategy, plans, expectations or intentions.
You should not place undue reliance on these statements. Such forward-looking
statements reflect the current views of the Group regarding future events, and
involve known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. There can be no
guarantee that the Group, or the OTC Division, will achieve any particular
financial results, whether as a result of the appointment of Brian McNamara, or
otherwise. In particular, management's expectations could be affected by, among
other things, unexpected regulatory actions or delays or government regulation
generally, including the potential further outcomes of our ongoing discussions
with health authorities concerning Rasilez/Tekturna® as a result of the ALTITUDE
study, and including the outcome of health authority reviews of the benefits and
risks of Gilenya®; unexpected product manufacturing issues, including the
potential outcomes of the Warning Letter issued to us with respect to three
Sandoz manufacturing facilities, and the potential outcome of the shutdown of
the OTC manufacturing facility at Lincoln, Nebraska; competition in general;
government, industry, and general public pricing pressures; unexpected clinical
trial results, including additional analyses of existing clinical data or
unexpected new clinical data, including any potential new analyses of the
ALTITUDE study which may occur; the Group's ability to obtain or maintain patent
or other proprietary intellectual property protection, including the ultimate
extent of the impact on the Group of the loss of patent protection on key
products which commenced last year and will continue this year; uncertainties
regarding actual or potential legal proceedings, including, among others, actual
or potential product liability litigation, litigation regarding sales and
marketing practices, shareholder litigation, government investigations and
intellectual property disputes; uncertainties regarding the after-effects of the
recent global financial and economic crisis; uncertainties regarding future
global exchange rates and uncertainties regarding future demand for our
products; uncertainties involved in the development of new healthcare products;
the impact that the foregoing factors could have on the values attributed to the
Group's assets and liabilities as recorded in the Group's consolidated balance
sheet; and other risks and factors referred to in Novartis AG's current Form 20-
F on file with the US Securities and Exchange Commission. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those described herein as
anticipated, believed, estimated or expected. Novartis is providing the
information in this presentation as of this date and does not undertake any
obligation to update any forward-looking statements as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and
diagnostic tools, over-the-counter and animal health products. Novartis is the
only global company with leading positions in these areas. In 2011, the Group's
continuing operations achieved net sales of USD 58.6 billion, while
approximately USD 9.6 billion (USD 9.2 billion excluding impairment and
amortization charges) was invested in R&D throughout the Group. Novartis Group
companies employ approximately 124,000 full-time-equivalent associates and
operate in more than 140 countries around the world. For more information,
please visithttp://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Pamela McKinlay
Novartis Global Media Relations Novartis OTC Communications
+41 61 324 7999 (direct) +1 973 503 7337 (direct)
+41 79 593 4202 (mobile) +1 862 221 0151 (mobile)
eric.althoff(at)novartis.com pamela.mckinlay(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please
contact:journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944 North America:
Susanne Schaffert +41 61 324 7944 Helen Boudreau +1 212 778 9375
Pierre-Michel Bringer +41 61 324 1065 Jill Pozarek +1 212 830 2445
Thomas Hungerbuehler +41 61 324 8425 Edwin Valeriano +1 212 830 2456
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/1590331/499590.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via Thomson Reuters ONE
[HUG#1590331]
Unternehmensinformation / Kurzprofil:
Datum: 29.02.2012 - 23:00 Uhr
Sprache: Deutsch
News-ID 120394
Anzahl Zeichen: 9598
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 407 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Brian McNamara Named Division Head, Novartis OTC"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
